Ketty Peris (K Peris)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 17

Top Topics

Systematic Review

Basal Cell Carcinoma

Atopic Dermatitis

Top Venues

Expert opinion on biological therapy

Dermatology research and practice

Expert opinion on investigational drugs

Scientific reports

This page only lists publications with an associated author ORCID identifier.

Publications

Eleonora De Luca, Pietro Sollena, Lucia Di Nardo, Ettore D'Argento, Emanuele Vita, Giampaolo Tortora, Ketty Peris
Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors. Dermatology research and practice 2024 (2024)
Eleonora De Luca, Pietro Sollena, Lucia Di Nardo, Ettore D'Argento, Emanuele Vita, Giampaolo Tortora, Ketty Peris
Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors. Dermatology research and practice 2024 (2024)
Giacomo Caldarola, Andrea Chiricozzi, Matteo Megna, P Dapavo, A Giunta, M Burlando, P Malagoli, V Dini, Marco Mariani, Gabriella Fabbrocini, P Quaglino, Luca Bianchi, A Parodi, Ketty Peris, C De Simone
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert opinion on biological therapy (2023)
Giacomo Caldarola, Andrea Chiricozzi, Matteo Megna, P Dapavo, A Giunta, M Burlando, P Malagoli, V Dini, Marco Mariani, Gabriella Fabbrocini, P Quaglino, Luca Bianchi, A Parodi, Ketty Peris, C De Simone
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert opinion on biological therapy (2023)
Laura Calabrese, Dalma Malvaso, Flaminia Antonelli, Maria Mannino, Ketty Peris, Andrea Chiricozzi
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? Expert opinion on investigational drugs (2023)
Niccolò Gori, Elena Ippoliti, Ketty Peris, Andrea Chiricozzi
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era. Expert opinion on biological therapy (2023)
Giacomo Caldarola, Eleonora De Luca, Marco Mariani, Andrea Chiricozzi, Ketty Peris, Clara De Simone
Drug survival of methotrexate and predictor factors for discontinuation in psoriasis. International journal of dermatology (2023)
Laura Calabrese, Dalma Malvaso, Flaminia Antonelli, Maria Mannino, Ketty Peris, Andrea Chiricozzi
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? Expert opinion on investigational drugs (2023)
E De Luca, N Gori, Andrea Chiricozzi, A Di Stefani, Ketty Peris
Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib. The Journal of dermatological treatment 33 (7) (2022)
Laura Calabrese, Andrea Chiricozzi, Clara De Simone, Barbara Fossati, Alessandra D'Amore, Ketty Peris
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis. Expert opinion on drug metabolism & toxicology 18 (5) (2022)
Andrea Chiricozzi, Niccolò Gori, Martina Maurelli, Paolo Gisondi, Giacomo Caldarola, Clara De Simone, Ketty Peris, Giampiero Girolomoni
Biological agents targeting interleukin-13 for atopic dermatitis. Expert opinion on biological therapy 22 (5) (2022)
Marco Galluzzo, Marina Talamonti, Nicoletta Bernardini, Andrea Chiricozzi, Clara De Simone, Claudio Bonifati, Pierluigi Bruni, Diotallevi Federico, Maria Esposito, Dario Graceffa, Katharina Hansel, Francesco Loconsole, Gaia Moretta, Cristina Mugheddu, Manuela Papini, Antonio Giovanni Richetta, Nevena Skroza, Laura Atzori, Maria-Concetta Fargnoli, Severino Persechino, Annamaria Offidani, Luca Stingeni, Ketty Peris, Concetta Potenza, Luca Bianchi
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert opinion on biological therapy (2022)
Marco Galluzzo, Giacomo Caldarola, C De Simone, N Bernardini, Gaia Moretta, Sabatino Pallotta, E Botti, Elena Campione, Federico Pirro, C Potenza, Luca Bianchi, Ketty Peris
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert opinion on biological therapy 21 (9) (2021)
Arianna Zangrilli, Giacomo Caldarola, Nicoletta Bernardini, Mauro Bavetta, Dario Graceffa, Claudio Bonifati, Franca Cantoresi, Sara Faleri, Domenico Giordano, Marco Mariani, Adriana Micheli, Gaia Moretta, Federico Pirro, Gianluca Pagnanelli, Vincenzo Panasiti, Alessia Provini, Antonio Giovanni Richetta, Lidia Sacchelli, Luca Bianchi, Ketty Peris
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy. Expert opinion on biological therapy 21 (9) (2021)
Lucia Di Nardo, Cristina Pellegrini, Alessandro Di Stefani, Francsesco Ricci, Barbara Fossati, Laura Del Regno, Carmine Carbone, Geny Piro, Vincenzo Corbo, Pietro Delfino, Simona De Summa, Maria Giovanna Maturo, Tea Rocco, Giampaolo Tortora, Maria-Concetta Fargnoli, Ketty Peris
Molecular alterations in basal cell carcinoma subtypes. Scientific reports 11 (1) (2021)
Marieke E C van Winden, Simone Garcovich, Ketty Peris, Giuseppe Ferdinando Colloca, Elke M G J de Jong, Marije E Hamaker, Peter Cornelis Maria van de Kerkhof, Satish F K Lubeek
Frailty screening in dermato-oncology practice: a modified Delphi study and a systematic review of the literature. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (1) (2020)
Andreas Wollenberg, Andrew Blauvelt, Emma Guttman-Yassky, Margitta Worm, C Lynde, Jean-Philippe Lacour, Lynda Spelman, Norito Katoh, Hidehisa Saeki, Y Poulin, A Lesiak, Leon Kircik, S H Cho, Pedro Herranz Pinto, Michael J Cork, Ketty Peris, L A Steffensen, B Bang, A Kuznetsova, T N Jensen, M L Østerdal, E L Simpson, null null
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). The British journal of dermatology 184 (3) (2020)